What is PrEP?
HIV-negative persons who are at high risk of becoming infected can prevent so-called pre-exposure prophylaxis. Patients are taking a drug that is also used to treat HIV and contains the active substances emtricitabine and tenofovir disoproxil fumarate. The efficacy is proven in homosexual men with risky sex life and similar to the use of condoms. However, the drug does not protect against other sexually transmitted diseases.
The prophylaxis is usually well tolerated, but can damage the kidneys. Users need to have their kidney function checked regularly and have an HIV test done every three months to prevent infection. Taking PrEP daily reduces the risk of HIV infection from sex with more than 90% and 70% of people injecting drugs. The risk of HIV infection can be further reduced by using PrEP and condoms.